Normal outcome of pregnancy with ongoing treatment with natalizumab.
Saved in:
| Title: | Normal outcome of pregnancy with ongoing treatment with natalizumab. |
|---|---|
| Authors: | Fagius, J., Burman, J. |
| Source: | Acta Neurologica Scandinavica. Jun2014, Vol. 129 Issue 6, pe27-e29. 3p. |
| Subjects: | Multiple sclerosis treatment, Natalizumab, Duration of pregnancy, First trimester of pregnancy, Gestational age |
| Abstract: | Background Treatment of multiple sclerosis ( MS) with natalizumab during pregnancy is not recommended due to potential risks for the foetus. Despite strong advice accidental pregnancies occur. Case A 32-year old woman with MS since the age of 26 was treated with natalizumab since January 2008. Treatment was stopped April 2011 due to pregnancy plans, but was restarted following an MS relapse. The patient was thoroughly informed about potential foetal risks, but nevertheless she one year later disclosed that she was pregnant in gestational week 15. Treatment was continued, since the first trimester had passed. The pregnancy course was normal and a healthy daughter was born at full gestational term. Conclusions This is the second known case where natalizumab treatment continued throughout the whole gestational period. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 95447458 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Normal outcome of pregnancy with ongoing treatment with natalizumab. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fagius%2C+J%2E%22">Fagius, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Burman%2C+J%2E%22">Burman, J.</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Jun2014, Vol. 129 Issue 6, pe27-e29. 3p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Multiple+sclerosis+treatment%22">Multiple sclerosis treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Natalizumab%22">Natalizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Duration+of+pregnancy%22">Duration of pregnancy</searchLink><br /><searchLink fieldCode="DE" term="%22First+trimester+of+pregnancy%22">First trimester of pregnancy</searchLink><br /><searchLink fieldCode="DE" term="%22Gestational+age%22">Gestational age</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background Treatment of multiple sclerosis ( MS) with natalizumab during pregnancy is not recommended due to potential risks for the foetus. Despite strong advice accidental pregnancies occur. Case A 32-year old woman with MS since the age of 26 was treated with natalizumab since January 2008. Treatment was stopped April 2011 due to pregnancy plans, but was restarted following an MS relapse. The patient was thoroughly informed about potential foetal risks, but nevertheless she one year later disclosed that she was pregnant in gestational week 15. Treatment was continued, since the first trimester had passed. The pregnancy course was normal and a healthy daughter was born at full gestational term. Conclusions This is the second known case where natalizumab treatment continued throughout the whole gestational period. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=95447458 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/ane.12222 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 3 StartPage: e27 Subjects: – SubjectFull: Multiple sclerosis treatment Type: general – SubjectFull: Natalizumab Type: general – SubjectFull: Duration of pregnancy Type: general – SubjectFull: First trimester of pregnancy Type: general – SubjectFull: Gestational age Type: general Titles: – TitleFull: Normal outcome of pregnancy with ongoing treatment with natalizumab. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fagius, J. – PersonEntity: Name: NameFull: Burman, J. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: Jun2014 Type: published Y: 2014 Identifiers: – Type: issn-print Value: 00016314 Numbering: – Type: volume Value: 129 – Type: issue Value: 6 Titles: – TitleFull: Acta Neurologica Scandinavica Type: main |
| ResultId | 1 |
